Miki Ohira
Overview
Explore the profile of Miki Ohira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okada R, Takenobu H, Satoh S, Sugino R, Onuki R, Haruta M, et al.
Genes Cells
. 2024 Aug;
29(10):838-853.
PMID: 39189159
Epigenetic alterations critically affect tumor development. Polycomb-group complexes constitute an evolutionarily conserved epigenetic machinery that regulates stem cell fate and development. They are implicated in tumorigenesis, primarily via histone modification....
2.
Yoneda A, Shichino H, Hishiki T, Matsumoto K, Ohira M, Kamijo T, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(6):e30976.
PMID: 38577760
Purpose: Survival rates of patients with high-risk neuroblastoma are unacceptable. A time-intensified treatment strategy with delayed local treatment to control systemic diseases has been developed in Japan. We conducted a...
3.
Tao K, Yamazaki F, Kubo T, Sunami K, Kumamoto T, Arakawa A, et al.
JCO Precis Oncol
. 2023 Jul;
7:e2200266.
PMID: 37410973
Purpose: This single-center, prospective molecular profiling study characterizes genomic alterations and identifies therapeutic targets in advanced pediatric solid tumors. Methods: As part of the TOP-GEAR (Trial of Onco-Panel for Gene...
4.
Parvin S, Akter J, Takenobu H, Katai Y, Satoh S, Okada R, et al.
BMC Cancer
. 2023 Apr;
23(1):313.
PMID: 37020276
Background: Genomic alterations, including loss of function in chromosome band 11q22-23, are frequently observed in neuroblastoma, which is the most common extracranial childhood tumour. In neuroblastoma, ATM, a DNA damage...
5.
Mukae K, Takenobu H, Endo Y, Haruta M, Shi T, Satoh S, et al.
Cancer Sci
. 2023 Jan;
114(5):1898-1911.
PMID: 36661413
Mesenchymal stem cell- or osteoblast-derived osteosarcoma is the most common malignant bone tumor. Its highly metastatic malignant phenotypes, which are often associated with a poor prognosis, have been correlated with...
6.
Sugino R, Ohira M, Mansai S, Kamijo T
BMC Genomics
. 2022 Dec;
23(1):852.
PMID: 36572864
Background: Neuroblastoma (NB) is the second most common pediatric solid tumor. Because the number of genetic mutations found in tumors are small, even in some patients with unfavorable NB, epigenetic...
7.
Akita N, Okada R, Mukae K, Sugino R, Takenobu H, Chikaraishi K, et al.
Exp Cell Res
. 2022 Nov;
422(1):113412.
PMID: 36370852
The overexpression of BMI1, a polycomb protein, correlates with cancer development and aggressiveness. We previously reported that MYCN-induced BMI1 positively regulated neuroblastoma (NB) cell proliferation via the transcriptional inhibition of...
8.
Shinno Y, Takenobu H, Sugino R, Endo Y, Okada R, Haruta M, et al.
Cancer Sci
. 2022 Sep;
113(12):4193-4206.
PMID: 36052716
In the present study, we found that EZH1 depletion in MYCN-amplified neuroblastoma cells resulted in significant cell death as well as xenograft inhibition. EZH1 depletion decreased the level of H3K27me1;...
9.
Shaliman D, Takenobu H, Sugino R, Ohira M, Kamijo T
Eur J Cell Biol
. 2022 May;
101(3):151238.
PMID: 35636260
Epigenetic modifications by polycomb repressive complex (PRC) molecules appear to play a role in the tumorigenesis and aggressiveness of neuroblastoma (NB). Embryonic ectoderm development (EED) is a member of the...
10.
Ohira M, Nakamura Y, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, et al.
Biomolecules
. 2022 Jan;
12(1).
PMID: 35053166
Neuroblastomas (NBs) exhibit broad and divergent clinical behaviors and tumor risk classification at diagnosis is crucial for the selection of an appropriate therapeutic strategy for each patient. The present study...